Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives
Reexamination Certificate
2008-12-05
2010-12-07
McGarry, Sean (Department: 1635)
Organic compounds -- part of the class 532-570 series
Organic compounds
Carbohydrates or derivatives
C536S023100, C536S024300, C536S024330, C435S006120, C435S091100, C435S325000, C435S375000, C514S04400A
Reexamination Certificate
active
07847090
ABSTRACT:
RNA interference using small interfering RNAs which are specific for the ICAM-1 gene inhibits expression of this gene. Diseases which involve ICAM-1-mediated cell adhesion, such as inflammatory and autoimmune diseases, diabetic retinopathy and other complications arising from type I diabetes, age related macular degeneration and many types of cancer, can be treated by administering the small interfering RNAs.
REFERENCES:
patent: 6015894 (2000-01-01), Bennett et al.
patent: 6096722 (2000-08-01), Bennett et al.
patent: 6177401 (2001-01-01), Ullrich et al.
patent: 6506559 (2003-01-01), Driver et al.
patent: 7195916 (2007-03-01), Qin et al.
patent: 2002/0086356 (2002-07-01), Tuschl et al.
patent: 2002/0132788 (2002-09-01), Lewis et al.
patent: 2002/0162126 (2002-10-01), Beach et al.
patent: 2002/0173478 (2002-11-01), Gewirtz
patent: 2004/0220129 (2004-11-01), Reich et al.
patent: 2005/0048529 (2005-03-01), McSwiggen
patent: 2005/0187174 (2005-08-01), Richards et al.
patent: 2359180 (2000-08-01), None
patent: WO 99/54341 (1999-10-01), None
patent: WO 02/44321 (2002-06-01), None
patent: WO 03/099298 (2003-12-01), None
Diallo et al., Long Endogenous dsRNAs Can Induce Complete Gene Silencing in Mammalian Cells and Primary Cultures, 2003, Oligonucleotides 13:381-392.
Rose et al., Functional Polarity is Introduced by Dicer Processing of Short Substrate RNAs, 2005, Nucleic Acids Research 33(13):4140-4156.
Nishiwaki et al., Introduction of Short Interfering RNA to Silence Endogenous E-Selectin in Vascular Endothelium Leads to Successful Inhibition of Leukocyte Adhesion, 2003, Biochemical and Biophysical Research Communications 310(4):1062-1066.
Warren et al., Successful ICAM-1 Gene Inactivation in Pluripotent Stem Cells Using RNA Interference and In Situ Expressed Antisense/Ribozyme Transgenes, 2002, J. Am. Soc. Nephrol., p. 101A (Abstract).
Devroe et al., Retrovirus-delivered siRNA, Aug. 28, 2002, BMC Biotechnology 2(15):1-5.
Kretschmer-Kazemi Far et al., The Activity of Sirna in Mammalian Cells is Related to Structural Target Accessibility: A Comparison With Antisense Oligonucleotides, 2003, Nucleic Acids Research 31(15):4417-4424.
Vickers et al., Efficient Reduction of Target RNAs by Small Interfering RNA and RNase H-dependent Antisense Agents, 2003, J. Biol. Chem. 278(9):7108-7118.
Katz et al., ICAM-1 Antisense Oligodeoxynucleotide Improves Islet Allograft Survival and Function, 2000, Cell Transplantation, 9:817-828.
Dragun et al., ICAM-1 Antisense Oligodesoxynucleotides Prevent Reperfusion Injury and Enhance Immediate Graft Function in Renal Transplantation, 1998, Kidney International, 54:590-602.
Elbashir et al., Duplexes of 21-Nucleotide RNAs Mediate RNA Interference in Cultured Mammalian Cells, 2001, Nature 411:494-498.
Agrawal et al., Antisense therapeutics: is it as simple as complementary base recognition? 2000, Molecular Medicine Today 6:72-81.
Jen et al., Suppression of Gene Expression by Targeted Disruption of Messenger RNA: Available Options and Current Strategies, 2000, Stem Cells 18:307-319.
Coburn et al., siRNAs: A New Wave of RNA-Based Therapeutics, 2003, Journal of Antimicrobial Chemotherapy 51:753-756.
Caplen, RNAi as a Gene Therapy Approach, 2003, Expert Opin. Biol. Ther. 3(4):575-586.
Agami, RNAi and Related Mechanisms and their Potential Use for Therapy, 2002, Current Opinion in Chemical Biology 6:829-834.
Hammond et al., Post-Transcriptional Gene Silencing by Double-Stranded RNA, 2001, Nature Reviews Genetics 2:110-119.
Bennett et al., Humoral Response after Administration of El -Deleted Adenoviruses: Immune Privilege of the Subretinal Space, 1996, Hum. Gene Ther. 7(14):1763-1769.
Elbashir et al., RNA Interference is Mediated by 21- and 22-Nucleotide RNAs, 2001, Genes & Development 15:188-200.
Erickson, RNAi Revs Up, Oct. 2002, Start-Up (A#2002900168), pp. 1-12.
Fire et al., Potent and Specific Genetic Interference by Double-Stranded RNA inCaenorhabditis elegans, Feb. 19, 1998, Nature 391:806-811.
Holash et al., VEGF-Trap: A VEGF Blocker with Potent Antitumor Effects, Aug. 20, 2002, PNAS 99(17):11393-11398.
Kim et al., Potent VEGF Blockade Causes Regression of Coopted Vessels in a Model of Neuroblastoma, Aug. 20, 2002, PNAS 99 (17):11399-11404.
Miyamoto et al., Vascular Endothelial Growth Factor (VEGF)-Induced Retinal Vascular Permeability is Mediated by Intercellular Adhesion Molecule-1 (ICAM-1), May 2000, American Journal of Pathology 156(5):1733-1739.
Miyamoto et al., Prevention of Leukostasis and Vascular Leakage in Streptozotocin-Induced Diabetic Retinopathy Via Intercellular Adhesion Molecule-1 Inhibition, Sep. 1999, Proc. Natl. Acad. Sci. USA 96:10836-10841.
Moromizato et al., CD18 and ICAM-1 Dependent Corneal Neovascularization and Inflammation after Limbal Injury, Oct. 2000, American Journal of Pathology 157(4):1277-1281.
Novina et al., siRNA-Directed Inhibition of HIV-1 Infection, Jul. 2002, Nature Medicine 8(7):681-686.
Sakurai et al., Targeted Disruption of the CD18 or ICAM-1 Gene Inhibits Choroidal Neovascularization, 2003, Investigative Opththalmology & Visual Science 44(6):2743-2749.
Tischer et al., The Human Gene for Vascular Endothelial Growth Factor. Multiple Protein Forms are Encoded through Alternative Exon Splicing, Jun. 25, 1991, J. Biol. Chem. 266(18):11947-11954 (Abstract).
Tuschl, The siRNA user guide (revised Oct. 11, 2002), Accessed from www.mpibpc.gwdg.de/abteilungen/100/105/sirna.html on Nov. 1, 2002.
Tuschl, Expanding small RNA interference, May 2002, Nature Biotechnology 20:446-448.
Van Brunt, Signals: The Online Magazine of Biotechnology Industry Analysis, Shoot the Messenger, Aug. 22, 2002, Accessed from www.signalsmag.com/signalsmag..../3DF5AEF6049C99256C1D0055BAA on Oct. 28, 2002.
Shu et al., Sphingosine Kinase Mediates Vascular Endothelial Growth Factor-Induced Activation of Rats and Mitogen-Activated Protein Kinases, Nov. 2002, Molecular and Cellular Biology 22:22:7758-7769.
Xia et al., siRNA-Mediated Gene Silencing in vitro and in vivo, Oct. 2002, Nature Biotechnology 20:1006-1010.
Downward, Science, Medicine, and the Future: RNA Interference, 2004, BMJ 328:1245-1248.
Paroo et al., Challenges for RNAI in vivo, 2004, Trends in Biotechnology 22(8):390-394.
Lu et al., Delivering siRNA in vivo for Functional Genomics and Novel Therapeutics, 2005, RNA Interference Techology: From Basic Science to Drug Development, Cambridge University Press, Cambridge, UK, Appasani ed., pp. 303-317.
Samarsky et al., RNAi in drug development: Practical considerations, 2005, RNA Interference Techology: From Basic Science to Drug Development Cambridge University Press, Cambridge, UK, Appasani ed., pp. 384-395.
Fjose et al., RNAi and MicroRNAs: From Animal Models to Disease Therapy, 2006, Birth Defects Research, 78:150-171.
Reich Samuel J.
Tolentino Michael J.
Gibbs Terra Cotta
McGarry Sean
Pepper Hamilton LLP
The Trustees of the University of Pennsylvania
LandOfFree
Compositions and methods for siRNA inhibition of ICAM-1 does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions and methods for siRNA inhibition of ICAM-1, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and methods for siRNA inhibition of ICAM-1 will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4161387